Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
21.76
-0.96 (-4.23%)
At close: Nov 2, 2026, 4:00 PM EST
21.77
+0.01 (0.05%)
After-hours: Nov 2, 2026, 7:30 PM EST
Tango Therapeutics Revenue
Tango Therapeutics had revenue of $53.81M in the twelve months ending June 30, 2026, up 121.47% year-over-year. In the year 2025, Tango Therapeutics had annual revenue of $62.38M with 48.29% growth. That makes Tango Therapeutics the 27,461st largest company in the world by revenue and 3,731st in the United States.
Revenue (ttm)
$53.81M
Revenue Growth
+121.47%
P/S Ratio
68.18
Revenue / Employee
$392,781
Employees
137
Market Cap
3.67B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.38M | 20.32M | 48.29% |
| Dec 31, 2024 | 42.07M | 5.54M | 15.17% |
| Dec 31, 2023 | 36.53M | 11.67M | 46.93% |
| Dec 31, 2022 | 24.86M | -12.18M | -32.89% |
| Dec 31, 2021 | 37.04M | 29.39M | 383.83% |
| Dec 31, 2020 | 7.66M | -16.99M | -68.94% |
| Dec 31, 2019 | 24.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Acadia Pharmaceuticals | 1.14B |
| Arcutis Biotherapeutics | 463.98M |
| Iovance Biotherapeutics | 324.97M |
| AbCellera Biologics | 66.17M |
| Relay Therapeutics | 10.35M |
| Xenon Pharmaceuticals | 7.50M |
TNGX News
- 7 days ago - Tango Therapeutics added to Analyst Focus List at JPMorgan - TheFly
- 10 days ago - Tango Therapeutics falls -12.6% - TheFly
- 10 days ago - Tango Therapeutics price target raised to $55 from $40 at Stifel - TheFly
- 10 days ago - Tango Therapeutics falls -17.5% - TheFly
- 10 days ago - Tango Therapeutics Transcript: Study result - Transcripts
- 10 days ago - Tango Therapeutics Press release: Study result - Filings
- 10 days ago - Tango Therapeutics Slides: Study result - Filings
- 10 days ago - Tango announces results from obngoing Phase 1/2 study of vopimetostat - TheFly